| Translate Bio, Inc. |
10%+ Owner |
Common Stock, par value $0.001 per share |
75,668,031 |
$2,875,385,178 |
$38.00 |
14 Sep 2021 |
Direct |
| MeiraGTx Holdings plc |
10%+ Owner |
Ordinary Shares ($0.00003881 par value per share) |
11,500,000 |
$73,140,000 |
$6.36 |
12 Aug 2024 |
Through its wholly-owned subsidiary, Sanofi Foreign Participations B.V. |
| Icosavax, Inc. |
10%+ Owner |
Common Stock (par value, $0.0001) |
3,155,169 |
$49,449,386 |
$15.67 |
02 Aug 2021 |
Through its wholly-owned subsidiary, Aventis Inc. |
| MeiraGTx Holdings plc |
10%+ Owner |
Ordinary Shares ($0.00003881 par value per share) |
697,737 |
$4,437,607 |
$6.36 |
12 Aug 2024 |
Through its wholly-owned subsidiary Kadmon Corporation, LLC |
| Icosavax, Inc. |
10%+ Owner |
Series A-1 Preferred Stock (par value, $0.0001) |
0 |
|
|
02 Aug 2021 |
Through its wholly-owned subsidiary, Aventis Inc |
| Icosavax, Inc. |
10%+ Owner |
Series B-1 Preferred Stock (par value, $0.0001) |
0 |
|
|
02 Aug 2021 |
Through its wholly-owned subsidiary, Aventis Inc |